Sign in

CIK 0001841387

  • Emerging growth company

Candel Therapeutics, Inc.

Sign in to watch
Ticker
CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
522214851
Phone
+1 617-916-5445
Business address
117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
  1. 4 Open-market buy Chief Scientific Officer bought 1,238 shares at $1.61 ($1,993)
  2. 4 Open-market buy Director bought 38,032 shares at an average $1.92 ($73,059)
  3. 4 Open-market buy Director bought 27,000 shares at an average $1.89 ($51,108)
  4. 4 Open-market buy Chief Executive Officer bought 15,985 shares at an average $1.88 ($30,020)
  5. 4 Open-market buy Chief Technology Officer bought 13,358 shares at an average $1.88 ($25,061)
  6. 4 Open-market buy Chief Financial Officer bought 5,568 shares at an average $1.80 ($10,002)
  7. 4 Grant or award Chief Financial Officer acquired 90,877 shares (grant or award)
  8. 4 Grant or award Chief Executive Officer acquired 195,906 shares (grant or award)
  9. 4 Grant or award Chief Scientific Officer acquired 90,877 shares (grant or award)
  10. 4 Grant or award Chief Medical Officer acquired 58,479 shares (grant or award)
  11. 4 Grant or award See Remarks acquired 73,684 shares (grant or award)
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 3 Insider Initial Statement of Ownership
  19. 4 Derivatives Options or other derivatives
  20. 3 Insider Initial Statement of Ownership

Page 8 of 11 · 202 filings